Nephrol Dial Transplant (2002) 17: 129-133
© 2002 European Renal Association-European Dialysis and Transplant Association
Severe evolution of chronic hepatitis C in renal transplantation: a case control study
1 Service d'Hépatologie et INSERM U-370, 2 Service de Transplantation Rénale, Hôpital Necker, 3 Laboratoire d'Anatomopathologie Hôpital Européen G. Pompidou and 4 Service de Transplantation Rénale, Hôpital Saint-Louis, Paris, France
Background. To evaluate the impact of kidney transplantation on histopathological progression of hepatitis C virus (HCV)-related liver disease.
Methods. In a retrospective study, 28 HCV-positive renal transplant patients, who underwent two sequential liver biopsies with a mean of 7.1±4.0 years, were compared with 28 matched immunocompetent controls.
Results. According to the Metavir score, the initial and final activity scores (from 0 to 3) increased from 0.2±0.4 to 1.4±1.1 (P<0.001) and those of fibrosis (from 0 to 4) from 0.5±0.5 to 2.0±1.4 (P<0.001) in the transplanted group, respectively, whereas the respective differences were not significant in the control group. The yearly progression rate of activity and fibrosis was significantly higher in the renal transplant group as compared with the immunocompetent group: 0.26±0.41 vs 0.01±0.19 (P<0.01) and 0.26±0.35 vs 0.05±0.21 (P<0.03), respectively. Twenty (71.5%) and 14 (50.0%) of the renal allograft recipients had activity and fibrosis progression as compared with four (16%) (P<0.001) and four (16%) (P<0.01) in immunocompetent patients; six kidney recipients (21.4%) evolved to cirrhosis vs only one in the control group (3.6%) (P=0.07). Liver-related mortality was significantly higher during the follow-up period in renal transplant patients than in the control group (10 vs 0%) (P<0.05).
Conclusion. Using conventional immunosuppressive regimen, renal transplantation is associated with a more severe evolution of chronic hepatitis C as compared with HCV-infected immunocompetent subjects. Thus, the histopathological evaluation should be performed and anti-viral therapy discussed before renal transplantation.
Keywords: HCV; immunocompromised; renal transplantation
*Both authors equally participated to the study.
Correspondence and offprint requests to: Stanislas Pol, MD, PhD, Unité d'Hépatologie, Hôpital Necker, 149 rue de Sèvres, F-75015 Paris, France. Email: stanislas.pol{at}nck.ap\|[hyphen]\|hop\|[hyphen]\|paris.fr
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. A. Terrault and D. B. Adey The Kidney Transplant Recipient with Hepatitis C Infection: Pre- and Posttransplantation Treatment Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 563 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Peffault de Latour, V. Levy, T. Asselah, P. Marcellin, C. Scieux, L. Ades, R. Traineau, A. Devergie, P. Ribaud, H. Esperou, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation Blood, March 1, 2004; 103(5): 1618 - 1624. [Abstract] [Full Text] [PDF]
|
|